TABLE 3.
Core and companion drugs and their bactericidal and sterilizing activities in the treatment of MDR-TB (long-course regimen)a
| Characteristics |
Use in MDR/XDR-TB treatment regimens |
|||||
|---|---|---|---|---|---|---|
| Drugs (grouping according to WHO) | Bactericidal activity | Sterilizing activity | Resistance prevention | Core drug | Companion drug used for its bactericidal or sterilizing effect | Other companion drugs |
| Group A | ||||||
| FQs (LFX and MFX) | High | High | High | X | ||
| BDQ | High | High | High? | X | ||
| LZD | High | Low | High | X | ||
| Group B | ||||||
| CFZ | Low | High | High | Sterilizing | ||
| Cycloserine or terizidone | Moderate | Low | Moderate | Bacteriostatic | ||
| Group C | ||||||
| EMB | Low | Low | Moderate | Bacteriostatic | ||
| DLM | High | High | High | X | ||
| PZA | Low | High | Low | Sterilizing | ||
| Imipenem-cilastatin OR meropenem | High | High | Moderate? | Bactericidal | ||
| Second-line injectables | ||||||
| Ethionamide or PTO | High | Low | High | Bacteriostatic and bactericidal | ||
| PAS | Moderate or high | Low | Moderate | Bacteriostatic | ||
| INH high-dose | Low or moderate | Low | High | Bactericidal | ||